How do recent ASCO updates influence lung cancer biomarker testing and treatment? (Webinar)
Home » How do recent ASCO updates influence lung cancer biomarker testing and treatment? (Webinar)

GH AMEA on Social MediaHow do recent ASCO updates influence lung cancer biomarker testing and treatment? (Webinar)
How do recent ASCO updates influence lung cancer biomarker testing and treatment? (Webinar)
How do recent ASCO updates influence lung cancer biomarker testing and treatment? (Webinar)
GH AMEA

Inviting all medical oncologists! Join us for a Webinar Discussion on how recent ASCO updates influence lung cancer biomarker testing and treatment. This webinar will feature a renowned medical oncologist, Prof. David Gandara, MD. from the U.S. and this session will be moderated by Prof. Myung Ju Ahn from South Korea. We look forward to your participation. Contact us at [email protected] to register before 10 August.

Visit us online @ guardanthealthamea.com

to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at [email protected] or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Message us